search

All clinical trials

Results 460281-460290 of 470744

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Relapsed NeuroblastomaMetastatic Pheochromocytoma

This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

No longer available32 enrollment criteria

Expanded Access for ACE-011

Myelodysplastic Syndrome

This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

No longer available2 enrollment criteria

Expanded Access for AG-221

Acute Myeloid Leukemia

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

No longer available2 enrollment criteria

Expanded Access for CC-486

Acute Myelogenous Leukemia (AML)

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.

Approved for marketing6 enrollment criteria

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Non-Small Cell Lung CancerALK Gene Rearrangement Positive

This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).

Available20 enrollment criteria

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)...

Urinary Tract InfectionsChronic Urinary Tract Infection3 more

An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.

No longer available3 enrollment criteria

Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are...

The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

Approved for marketing2 enrollment criteria

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3...

Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations

The purpose of this study is to provide expanded access to gilteritinib (ASP2215) for patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) or with FLT3-mutated AML in composite complete remission (CRc: [complete remission (CR), complete remission with incomplete hematologic recovery (CRi), complete remission with incomplete platelet recovery (CRp)]) with minimal residual disease (MRD) without access to comparable or alternative therapy.

No longer available33 enrollment criteria

Expanded Access to NanoDoce

Urogenital Neoplasms

NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

Available2 enrollment criteria

Expanded Access to Elezanumab

Acute Spinal Cord Injury (SCI)Acute Ischemic Stroke

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available1 enrollment criteria
1...460284602946030...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs